Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fanwei Meng

Internal Medicine Columbia, SC Medical Doctor

NPI 1780650937 CMS profile 172029

21 Gateway Corners Park Ste 101, Columbia, SC 29203

Open in the dashboard

General payments

$4,314

238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fanwei Meng of Columbia, SC is reported in the CMS Open Payments database as having received $4,314 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,407 76
2024 General $1,475 79
2023 General $800 44
2022 General $559 34
2020 General $49 3
2019 General $24 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fanwei Meng
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Fanwei Meng were reported at $1,407. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Fanwei Meng Internal Medicine median Middle half National median
2019 $24 $159 $48–$570 $163
2020 $49 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $559 $141 $42–$496 $149
2023 $800 $149 $45–$519 $160
2024 $1,475 $154 $47–$537 $164
2025 $1,407 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $570 37 payments
  2. Dexcom, Inc. $518 14 payments
  3. AbbVie, Inc. $473 39 payments
  4. Novo Nordisk Inc $382 21 payments
  5. AstraZeneca Pharmaceuticals LP $340 21 payments
  6. Pfizer Inc. $312 18 payments
  7. Amgen Inc. $229 11 payments
  8. Abbott Laboratories $199 10 payments
  9. Sanofi-Aventis U.S. LLC $128 7 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $121 7 payments
  11. Other $1,043 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,289 237 payments
  2. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. Dexcom G6 Transmitter $518 14 payments
  2. MOUNJARO $490 31 payments
  3. ZEPBOUND $264 16 payments
  4. Ozempic $255 13 payments
  5. RYBELSUS $255 13 payments
  6. NURTEC ODT $251 14 payments
  7. FARXIGA $234 14 payments
  8. Otezla $202 9 payments
  9. UBRELVY $182 15 payments
  10. VRAYLAR $176 14 payments
  11. Other $2,972 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

5,548

Median for Internal Medicine: 777

Drug cost

$510,113

Median for Internal Medicine: $73,373

Branded share of claims

19.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 95 $127,154
Eliquis Apixaban Brand 94 $71,213
Mounjaro Tirzepatide Brand 44 $55,180
Ozempic Semaglutide Brand 28 $40,339
Trulicity Dulaglutide Brand 33 $38,997
Farxiga Dapagliflozin Propanediol Brand 22 $26,368
Xarelto Rivaroxaban Brand 19 $20,176
Entresto Sacubitril/Valsartan Brand 21 $14,859
Linzess Linaclotide Brand 16 $13,544
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $10,781

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$71,878

Of which drugs: $3,751

Medicare patients

175

Average age 72

Services billed

1,468

90 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 31%
Ischemic heart disease 31%
Chronic kidney disease 29%
Depression 19%
Heart failure 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $138
$138 44 —
VRAYLAR
  • AbbVie, Inc. $115
$115 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $91
$91 22 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
  • Lilly USA, LLC $30
$66 95 —
RYBELSUS
  • Novo Nordisk Inc $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record